Detection of high-risk human papilloma virus in women within the framework of the second stage of the pilot project "ОНКОПОИСКСАХА.РФ" in Yakutia
L. N. Afanasyeva,
E. V. Filippov,
G. V. Filippova,
P. V. Nikiforov,
T. I. Nikolaeva,
N. A. Larionova,
M. S. Struchkova https://doi.org/10.25789/YMJ.2023.84.17
Abstract
The study was conducted in 2022 as part of the implementation of the second stage of the pilot project "ОНКОПОИСКСАХА.РФ" (ONCO-SEARCH) at the Yakut Republican Oncology Dispensary, which is part of the national project "Healthcare". The project involved 798 women from 10 districts of the Republic of Sakha (Yakutia). The comprehensive examination included cytological testing, detection and genotyping of high carcinogenic risk human papillomavirus (HСR-HPV) using polymerase chain reaction, and assessment of viral load. The territorial distribution of HСR-HPV types was demonstrated. The overall infection rate among women ranged from 6.9% (Tomponsky district) to 25.0% (Oymyakon district), with an average of 14.8%. The majority of infections were of the episomal - non-integrated form of HPV. Differences in infection rates among women of different age groups were observed. The highest pro-portion of HCR-HPV carriers, including integrated forms, was found in the age groups of 20-30 and 31-40 years. High-grade squamous intraepithelial lesions (HSIL) were diagnosed in 2.5% of the examined women, while low-grade squamous intraepithelial lesions (LSIL) were found in 1.8%. One woman was diagnosed with squamous cell carcinoma. The study showed a correlation between viral load, integrated forms of HPV, and cervical intraepithelial neoplasia (CIN). The integrated form of genotype 16 made the largest contribution (50%) to CIN lesions among HCR-HPV-infected individuals.
About the Authors
L. N. Afanasyeva
M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Afanasyeva Lena Nikolaevna – PhD, Associate Professor
E. V. Filippov
State Budgetary Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncological Dispensary
Russian Federation
Russian Federation
Filippov Eduard Vasilyevich – PhD in Biology, Head of Molecular Biology Laboratory
G. V. Filippova
State Budgetary Institution of the Yakut Republic of
Sakha (Yakutia) Yakut Republican Oncological Dispensary; Siberian Branch of Russian Academy
of Sciences
Russian Federation
Russian Federation
Filippova Galina Valerievna – PhD in Biology, Pathological and Anatomical laboratory; Senior Re-searcher of the Institute for Biological Problems of Cryolithozone
P. V. Nikiforov
State Budgetary Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensary; Federal State Autonomous Educational Institution of Higher Education M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Nikiforov Petr Vladimirovich – Deputy Chief Physician; Associate Professor
T. I. Nikolaeva
State Budgetary Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensary; Federal State Autonomous Educational Institution of Higher Education M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Nikolaeva Tatyana Ivanovna – PhD in Medicine, Chief Physician; Associate Professor
N. A. Larionova
State Budgetary Institution of the State Budgetary
Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncological Dispensary
Russian Federation
Russian Federation
Larionova Natalya Abdraim-zhan – Head of the Cytological Laboratory
M. S. Struchkova
Budgetary Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensary
Russian Federation
Russian Federation
Struchkova Monika Sergeevna – oncogynecologist of the Department of Oncogynecology
References
1. Detecting the human papilloma virus of high carcinogenic risk in women within the framework of the I stage of the Oncopoisk program in Yakutia/ Afanasieva L.N., Filippov E.V., Filippova G.V., Nikiforov P.V., Nikolaeva T.I. // Yakut medical journal. 2022. No. 3 (79). P.53-56. doi:10.25789/YMJ.2022.79.14.
2. Integrative and episomal forms of genotype 16 of the human papillomavirus in cervical intraepithelial neoplasia and cervical cancer/ Ibragimova M.K., Tsyganov M.M., Karabut I.V.[et all.] //Problems of Virology. 2016; 61(6): 270-274. DOI: 10.18821/0507-4088-2016-61-6-270-274.
3. . Kaprin A. D., Starinsky V. V., Petrova G. M. Malignant neoplasms in Russia in 2018 (incidence and mortality). Herzen MNIOI, 2019. P. 236.
4. Comprehensive cervical cancer prevention and control: a healthier future for girls and women / WHO guidance note. 2013
5. Mazurenko N.N. The role of papillomaviruses in carcinogenesis of the cervix // Modern Oncology. 2003. V.5 No.1.P.37-44.
6. The Prevalence of Papillomavirus Infection in Russia / Rogovskaya S.I., Mikheeva I.V., Shipulina O.Yu. [et al]. // Epidemiology and vaccine prevention. 2012. No. 1 (62). P. 25-33.
7. Afanasieva L.N., Ignatieva M.E., Lialina L.V., Savvina N.V., Smetanina V.D. Regional experience in the prevention of cervical cancer in the Republic of Sakha (Yakutia). Infection and Immunity 2014, Vol. 4, No. 2. P. 137–142.
8. Bosch F.X. Human papillomavirus: science and technologies for the elimination of cervical cancer// Expert Opin Pharmacother.2011. V.12 (14). P.2189-2204.
9. Buchanan TR, Graybill WS, Pierce JY. Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. Hum Vaccines Immunother. (2016) 12:1352–6. doi: 10.1080/21645515.2016.1147634.
10. Castle PE et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011 Sep;12(9): 880-90.
11. Chan C.K., Aimagambetova G., Ukybassova T., Kongrtay K., Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives (англ.) // Journal of Oncology: journal. – 2019. – 10 October (vol. 2019). – P. 3257939. – doi:10.1155/2019/3257939.
12. Debbie Saslow et.al. American Society for colposcopy and Cervical Patology, and American So-ciety for Clinical Patology Screening Guidelines for the Prevention and Early Detection of Cer-vical Cancer. CA CANCER J CLIN 2012; 62:147-172.
13. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. (2012) 13:607-15. doi: 10.1016/S1470-2045(12)70137-7.
14. De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. (2017) 141:664-70. doi: 10.1002/ijc.30716.
15. De Villiers, E.M., L. Gissmann, and H. zur Hausen.1981. Molecular cloning of viral DNA from human genital warts. J. Virol.40:932-935.
16. Fontham ETH, Wolf AMD, Church TR, Etzioni R, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020 Sep;70(5):321-346.)
17. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. (2012) 30: F12–23. doi: 10.1016/j.vaccine.2012.07.055.
18. Hu Z., Zhu D., Wang W., Li W., Jia W., Zeng X. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat. Genet. 2015; 47(2): 158-63.
19. Kachalina O.V., Kontorshchikova K.N., Andosova L.D. Modern ideas about the role of human papillomavirus in the genesis of cervical cancer (Review). Meditsinskiy al’manakh. 2011; (5): 116-20. (in Russian).
20. Mark Schiffman, Philip E. Castle. The Promise of Global Cervical-Cancer Prevention List of authors. The New England Journal of Medicine 2005 17 ноября; 353 (20): 2101-4. doi: 10.1056/NEJMp058171.
21. Matlashewski G. /Anticancer Res. 1989. No.9. P.1447-1456.
22. Vink M.A., Bogaards J.A., Meijer C.J. Clinical progression of highgrade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am. J. Epidemiol. 2013; 178(7): 1161-9.
23. World Health Organization. Global Strategy to accelerate the elimination of cervical cancer as a public health problem https://www.who.int/publications/i/item/9789240014107 Accessed August 22, 2021.
24. https://medstatistic.ru/calculators.html (онлайн-сервис для статистической обработки данных медицинских исследований)
Review
For citations:
Afanasyeva L.N., Filippov E.V., Filippova G.V., Nikiforov P.V., Nikolaeva T.I., Larionova N.A., Struchkova M.S. Detection of high-risk human papilloma virus in women within the framework of the second stage of the pilot project "ОНКОПОИСКСАХА.РФ" in Yakutia. Yakut Medical Journal. 2023;(4):68-74. https://doi.org/10.25789/YMJ.2023.84.17
Views:
21
Email this article 